---
annotation-target: cir-22-0434.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-20T12:03:42.834Z","updated":"2022-09-20T12:03:42.834Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":91,"end":182},{"type":"TextQuoteSelector","exact":"Immune  phenotypes  and  target  antigens  of  clonally  expanded  bone  marrow  T  cells  ","prefix":"n multiple myeloma Page 1 of 42 ","suffix":"in  treatment-naïve multiple mye"}]}]}
>```
>%%
>*%%PREFIX%%n multiple myeloma Page 1 of 42%%HIGHLIGHT%% ==Immune  phenotypes  and  target  antigens  of  clonally  expanded  bone  marrow  T  cells== %%POSTFIX%%in  treatment-naïve multiple mye*
>%%LINK%%[[#^iiqrsw4dhs|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^iiqrsw4dhs


>%%
>```annotation-json
>{"created":"2022-09-20T12:08:54.909Z","text":"从未接受治疗患者","updated":"2022-09-20T12:08:54.909Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":3038,"end":3072},{"type":"TextQuoteSelector","exact":"treatment-naïve  multiple  myeloma","prefix":"ll  level were  determined  in  ","suffix":".  Dominant  T-cell  clones  rar"}]}]}
>```
>%%
>*%%PREFIX%%ll  level were  determined  in%%HIGHLIGHT%% ==treatment-naïve  multiple  myeloma== %%POSTFIX%%.  Dominant  T-cell  clones  rar*
>%%LINK%%[[#^49u0ipn30j7|show annotation]]
>%%COMMENT%%
>从未接受治疗患者
>%%TAGS%%
>
^49u0ipn30j7


>%%
>```annotation-json
>{"created":"2022-09-20T12:10:06.154Z","updated":"2022-09-20T12:10:06.154Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":3594,"end":3807},{"type":"TextQuoteSelector","exact":"i)  were  detectable  in  multiple  myeloma  bone marrow,  ii)  showed  characteristic  immune  phenotypes,  and  iii)  whether  dominant  clones recognized antigens selectively presented on multiple myeloma cells","prefix":"  clonally  expanded  T  cells  ","suffix":". Single-cell index sorting and "}]}]}
>```
>%%
>*%%PREFIX%%clonally  expanded  T  cells%%HIGHLIGHT%% ==i)  were  detectable  in  multiple  myeloma  bone marrow,  ii)  showed  characteristic  immune  phenotypes,  and  iii)  whether  dominant  clones recognized antigens selectively presented on multiple myeloma cells== %%POSTFIX%%. Single-cell index sorting and*
>%%LINK%%[[#^b5pon0rce4|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^b5pon0rce4


>%%
>```annotation-json
>{"created":"2022-09-20T12:11:01.205Z","updated":"2022-09-20T12:11:01.205Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":3915,"end":4771},{"type":"TextQuoteSelector","exact":"13  treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classical immune checkpoint molecules PD-1,  CTLA-4,  or  TIM-3.  To  identify  their  molecular  targets,  TCRs  of  68  dominant  bone marrow  clones  from  five selected  patients  were  re-expressed  and  incubated  with  multiple myeloma  and  non-multiple  myeloma  cells  from  corresponding  patients.  Only  one  out  of  68 TCRs  recognized  antigen  presented  on  multiple  myeloma  cells.  This  TCR  was  HLA-C-restricted, self-peptide-specific, and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infection","prefix":"  bone  marrow  T  cells  from  ","suffix":"s. In conclusion, we showed that"}]}]}
>```
>%%
>*%%PREFIX%%bone  marrow  T  cells  from%%HIGHLIGHT%% ==13  treatment-naïve patients showed dominant clonal expansion within CD8+ cytolytic effector compartments, and only a minority of expanded T-cell clones expressed the classical immune checkpoint molecules PD-1,  CTLA-4,  or  TIM-3.  To  identify  their  molecular  targets,  TCRs  of  68  dominant  bone marrow  clones  from  five selected  patients  were  re-expressed  and  incubated  with  multiple myeloma  and  non-multiple  myeloma  cells  from  corresponding  patients.  Only  one  out  of  68 TCRs  recognized  antigen  presented  on  multiple  myeloma  cells.  This  TCR  was  HLA-C-restricted, self-peptide-specific, and could be activated by multiple myeloma cells of multiple patients. The remaining dominant T-cell clones did not recognize multiple myeloma cells and were, in part, specific for antigens associated with chronic viral infection== %%POSTFIX%%s. In conclusion, we showed that*
>%%LINK%%[[#^9lbibud5iw5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9lbibud5iw5


>%%
>```annotation-json
>{"created":"2022-09-20T12:11:21.528Z","updated":"2022-09-20T12:11:21.528Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":5248,"end":5434},{"type":"TextQuoteSelector","exact":"ur  data  provide  experimental  context  for  experiences  from  clinical immune  checkpoint  inhibition  trials  and  will  inform  future  T  cell-dependent  therapeutic strategies.  ","prefix":"immune checkpoint  molecules.  O","suffix":"  Downloaded from http://aacrjou"}]}]}
>```
>%%
>*%%PREFIX%%immune checkpoint  molecules.  O%%HIGHLIGHT%% ==ur  data  provide  experimental  context  for  experiences  from  clinical immune  checkpoint  inhibition  trials  and  will  inform  future  T  cell-dependent  therapeutic strategies.== %%POSTFIX%%Downloaded from http://aacrjou*
>%%LINK%%[[#^5mw4lnd53lr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5mw4lnd53lr


>%%
>```annotation-json
>{"created":"2022-09-20T12:12:13.241Z","updated":"2022-09-20T12:12:13.241Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":5818,"end":6040},{"type":"TextQuoteSelector","exact":"Immune cells constituting the bone marrow microenvironment have a major role in disease pathophysiology (1-3), and immunomodulatory agents, as well as monoclonal antibodies, are part of effective treatment regimens (4,5). ","prefix":"lasma cells in the bone marrow. ","suffix":"Clonal T-cell expansion is an an"}]}]}
>```
>%%
>*%%PREFIX%%lasma cells in the bone marrow.%%HIGHLIGHT%% ==Immune cells constituting the bone marrow microenvironment have a major role in disease pathophysiology (1-3), and immunomodulatory agents, as well as monoclonal antibodies, are part of effective treatment regimens (4,5).== %%POSTFIX%%Clonal T-cell expansion is an an*
>%%LINK%%[[#^6whoarnejkg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^6whoarnejkg


>%%
>```annotation-json
>{"created":"2022-09-20T12:12:58.891Z","updated":"2022-09-20T12:12:58.891Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":6332,"end":6881},{"type":"TextQuoteSelector","exact":"The  peripheral  blood  of  heavily  pre-treated  multiple  myeloma  patients  can  contain  variable amounts of neoantigen-specific T cells (10); however, their occurrence in the bone marrow of treatment-naïve  patients,  degrees  of  clonal  expansion,  impact  on  multiple  myeloma pathophysiology,  and  clinical  significance  remain  unclear.  Tumor  mutational  burden,  which correlates with presence of tumor-specific T cells and response to immune checkpoint inhibition in solid tumors, can be considered intermediate in multiple myeloma ","prefix":"sted T-cell compartments (6-9). ","suffix":"(11) and increases with the numb"}]}]}
>```
>%%
>*%%PREFIX%%sted T-cell compartments (6-9).%%HIGHLIGHT%% ==The  peripheral  blood  of  heavily  pre-treated  multiple  myeloma  patients  can  contain  variable amounts of neoantigen-specific T cells (10); however, their occurrence in the bone marrow of treatment-naïve  patients,  degrees  of  clonal  expansion,  impact  on  multiple  myeloma pathophysiology,  and  clinical  significance  remain  unclear.  Tumor  mutational  burden,  which correlates with presence of tumor-specific T cells and response to immune checkpoint inhibition in solid tumors, can be considered intermediate in multiple myeloma== %%POSTFIX%%(11) and increases with the numb*
>%%LINK%%[[#^9cp1tuw2xu5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^9cp1tuw2xu5


>%%
>```annotation-json
>{"created":"2022-09-20T12:16:10.936Z","updated":"2022-09-20T12:16:10.936Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":7108,"end":7390},{"type":"TextQuoteSelector","exact":"However, immune checkpoint blockade targeting PD-1/PD-L1 interactions to reverse functional T-cell inhibition has been ineffective as a monotherapy in multiple myeloma (14) and has led to increased severe adverse events without improving clinical responses in combination therapies ","prefix":" disease  progression  (12,13). ","suffix":"(15,16).  Furthermore,  multiple"}]}]}
>```
>%%
>*%%PREFIX%%disease  progression  (12,13).%%HIGHLIGHT%% ==However, immune checkpoint blockade targeting PD-1/PD-L1 interactions to reverse functional T-cell inhibition has been ineffective as a monotherapy in multiple myeloma (14) and has led to increased severe adverse events without improving clinical responses in combination therapies== %%POSTFIX%%(15,16).  Furthermore,  multiple*
>%%LINK%%[[#^k9txlcxp6y|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^k9txlcxp6y


>%%
>```annotation-json
>{"created":"2022-09-20T12:16:37.770Z","updated":"2022-09-20T12:16:37.770Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":7957,"end":8108},{"type":"TextQuoteSelector","exact":"we studied differentiation states and specificities of dominant bone marrow T-cell  clones  in  treatment-naïve  patients  at  the  single-cell  level.","prefix":"le myeloma-associated antigens, ","suffix":"  We  investigated  whether  i) "}]}]}
>```
>%%
>*%%PREFIX%%le myeloma-associated antigens,%%HIGHLIGHT%% ==we studied differentiation states and specificities of dominant bone marrow T-cell  clones  in  treatment-naïve  patients  at  the  single-cell  level.== %%POSTFIX%%We  investigated  whether  i)*
>%%LINK%%[[#^1uyk1v8dbe3|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^1uyk1v8dbe3


>%%
>```annotation-json
>{"created":"2022-09-20T12:20:02.807Z","updated":"2022-09-20T12:20:02.807Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":8110,"end":8387},{"type":"TextQuoteSelector","exact":"We  investigated  whether  i) clonal expansion was restricted to bone marrow T cells, ii) clonal T-cell expansion associated with characteristic immune phenotypes, and iii) dominant bone marrow T-cell clones recognized antigens selectively presented on multiple myeloma cells. ","prefix":"  at  the  single-cell  level.  ","suffix":"   MATERIALS AND METHODS Patient"}]}]}
>```
>%%
>*%%PREFIX%%at  the  single-cell  level.%%HIGHLIGHT%% ==We  investigated  whether  i) clonal expansion was restricted to bone marrow T cells, ii) clonal T-cell expansion associated with characteristic immune phenotypes, and iii) dominant bone marrow T-cell clones recognized antigens selectively presented on multiple myeloma cells.== %%POSTFIX%%MATERIALS AND METHODS Patient*
>%%LINK%%[[#^20h698thmhp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^20h698thmhp


>%%
>```annotation-json
>{"created":"2022-09-20T12:35:51.053Z","updated":"2022-09-20T12:35:51.053Z","document":{"title":"cir-22-0434.pdf","link":[{"href":"urn:x-pdf:9ec914dc46938f334b46858ab743036c"},{"href":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf"}],"documentFingerprint":"9ec914dc46938f334b46858ab743036c"},"uri":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220920/cir-22-0434.pdf","selector":[{"type":"TextPositionSelector","start":15682,"end":15714},{"type":"TextQuoteSelector","exact":"Multiple myeloma cell lines U266","prefix":"myeloma Page 9 of 42 Cell lines ","suffix":"B1 (RRID: CVCL_0566), JJN-3 (RRI"}]}]}
>```
>%%
>*%%PREFIX%%myeloma Page 9 of 42 Cell lines%%HIGHLIGHT%% ==Multiple myeloma cell lines U266== %%POSTFIX%%B1 (RRID: CVCL_0566), JJN-3 (RRI*
>%%LINK%%[[#^e9zqlj9mzut|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^e9zqlj9mzut
